Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 4/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.49 |
| ▸ | CDK8 | P49336 | 6/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19341716 | 1.00 | BCL2 (0.49) | BCL2BCL2L1CDK8CHEK1KDR | |
| SCHEMBL16030568 | 0.89 | BCL2 (0.57) | BCL2BCL2L1CDK8CHEK1KDR | |
| SCHEMBL19332922 | 0.88 | CDK8 (0.43) | BCL2BCL2L1CDK8KDRTNIK | |
| SCHEMBL29403244 | 0.87 | RIPK1 (0.45) | BCL2BCL2L1CDK8KDRTNIK | |
| SCHEMBL20578175 | 0.86 | BCL2 (0.49) | BCL2BCL2L1CDK8KDRTNIK | |
| SCHEMBL523456 | 0.86 | CDK8 (0.49) | BCL2BCL2L1CDK8KDRTNIK | |
| SCHEMBL31427495 | 0.86 | CDK8 (0.49) | BCL2BCL2L1CDK8KDRTNIK | |
| SCHEMBL24165693 | 0.86 | BCL2 (0.48) | BCL2BCL2L1CDK8KDRTNIK | |
| SCHEMBL19867779 | 0.85 | BCL2 (0.48) | BCL2BCL2L1CDK8KDRTNIK | |
| SCHEMBL19867929 | 0.85 | CDK8 (0.52) | BCL2BCL2L1CDK8KDRTNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496239-A | Synthesis method of key intermediate and bulk drug of vitamin Nadotox | 南京哈柏医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116496239-A | Synthesis method of key intermediate and bulk drug of vitamin Nadotox | 南京哈柏医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4199924-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| US-20230119463-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. | 2023-04-20 | — | — | US | disclosed |
| CN-114073703-B | Compositions and methods for treating nonalcoholic steatohepatitis | 苏州亚盛药业有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-110483501-B | N- (phenylsulfonyl) benzamides and related compounds as BCL-2 inhibitors | 密歇根大学董事会 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022140224-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220073513-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022037683-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022037684-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-02-24 | — | — | WO | disclosed |
| CN-114073703-A | Compositions and methods for treating nonalcoholic steatohepatitis | 苏州亚盛药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-114073707-A | Compositions and methods for treating systemic lupus erythematosus | 苏州亚盛药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073513-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | BCL2, BCL2A1, BCL3 | BCL2 1/4885BCL2L1 4/4885CDK8 766/4885 |
| US-20230119463-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | BCL2, BAK1, BCL2A1 | BCL2 1/4885BCL2L1 4/4885CDK8 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.